NCT06600399

Brief Summary

Evaluating the relationship between prostate-specific membrane antigen positron emission tomography and arterial spin labeling perfusion imaging, and the correlation with prostate-specific membrane antigen expressed on glioblastoma microvascular.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2022

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 29, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 29, 2024

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 4, 2024

Completed
15 days until next milestone

First Posted

Study publicly available on registry

September 19, 2024

Completed
Last Updated

September 19, 2024

Status Verified

September 1, 2024

Enrollment Period

1.4 years

First QC Date

September 4, 2024

Last Update Submit

September 13, 2024

Conditions

Glioblastoma

Keywords

Prostate-specific membrane antigenArterial spin labeling

Outcome Measures

Primary Outcomes (1)

  • The similarity of biological information

    Evaluating the similarity of biological information captured by prostate-specific membrane antigen positron emission tomography and arterial spin labeling perfusion imaging in glioblastoma.

    2 week

Study Arms (1)

Correlation between PSMA PET and ASL

The relationship between multimodal images

Diagnostic Test: glioblastoma

Interventions

glioblastomaDIAGNOSTIC_TEST

All patients underwent conventional MRI, ASL perfusion imaging and 68Ga-PSMA-11 PET/CT examinations within 1 week interval

Correlation between PSMA PET and ASL

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Twenty-six patients with newly diagnosed or recurrent glioblastoma who underwent conventional MRI, ASL and PSMA PET were prospectively enrolled

You may qualify if:

  • Newly diagnosed or recurrent glioblastoma;
  • Adult (≥18 years old);

You may not qualify if:

  • The patient has a serious underlying disease or mental illness and is unable to cooperate with the imaging examination;
  • Have received systematic chemotherapy;
  • The image data is of poor or incomplete quality;
  • pregnant women;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Second Hospital of Lanzhou University

Lanzhou, Gansu, 730000, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

The expression of prostate-specific membrane antigen in glioblastoma multiforme microvascular was analyzed by immunohistochemistry in tissue samples obtained after surgical resection.

MeSH Terms

Conditions

Glioblastoma

Condition Hierarchy (Ancestors)

AstrocytomaGliomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
chief physician

Study Record Dates

First Submitted

September 4, 2024

First Posted

September 19, 2024

Study Start

October 1, 2022

Primary Completion

February 29, 2024

Study Completion

February 29, 2024

Last Updated

September 19, 2024

Record last verified: 2024-09

Locations

CN(1)